Journal article

A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer

Hui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, Piyushkumar A Mundra, Calan Spielman, Karen Briscoe, Howard Gurney, Girish Mallesara, Gavin Marx, Martin R Stockler, Robert G Parton, Andrew J Hoy, Roger J Daly, Peter J Meikle, Lisa G Horvath



Lipids are known to influence tumour growth, inflammation and chemoresistance. However, the association of circulating lipids with the clinical outcome of metastatic castration-resistant prostate cancer (CRPC) is unknown. We investigated associations between the plasma lipidome and clinical outcome in CRPC. Lipidomic profiling by liquid chromatography-tandem mass spectrometry was performed on plasma samples from a Phase 1 discovery cohort of 96 CRPC patients. Results were validated in an independent Phase 2 cohort of 63 CRPC patients. Unsupervised analysis of lipidomic profiles (323 lipid species) classified the Phase 1 cohort into two patient subgroups with significant survival differences ..

View full abstract


Awarded by National Health and Medical Research Council of Australia

Awarded by Cancer Institute New South Wales

Awarded by Cancer Council New South Wales

Funding Acknowledgements

Grant sponsor: National Health and Medical Research Council of Australia; Grant numbers: 1042095 (to P.J.M.), 1058540 (to R.J.D.) and 535903; Grant sponsor: Operational Infrastructure Support Program of the Victorian Government; Grant sponsor: Cancer Institute New South Wales; Grant number: 10/TPG/1-04; Grant sponsor: Cancer Council New South Wales; Grant number: PG 10-01; Grant sponsor: Prostate Cancer Foundation of Australia (Movember Clinician Scientist Award to K.L.M., Movember Revolutionary Team Award to A.J.H.)